## Koki Mise

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7322538/publications.pdf

Version: 2024-02-01

76	1,349	394286	395590
papers	1,349 citations	h-index	g-index
76	76	76	1761
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease. Nature Communications, 2019, 10, 1835.	5.8	173
2	Prognostic Value of Tubulointerstitial Lesions, Urinary N-Acetyl-β-D-Glucosaminidase, and Urinary β2-Microglobulin in Patients with Type 2 Diabetes and Biopsy–Proven Diabetic Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 593-601.	2.2	93
3	Renal prognosis a long time after renal biopsy on patients with diabetic nephropathy. Nephrology Dialysis Transplantation, 2014, 29, 109-118.	0.4	78
4	Nonproteinuric Versus Proteinuric Phenotypes in Diabetic Kidney Disease: A Propensity Score–Matched Analysis of a Nationwide, Biopsy-Based Cohort Study. Diabetes Care, 2019, 42, 891-902.	4.3	77
5	Nationwide multicentre kidney biopsy study of Japanese patients with type 2 diabetes. Nephrology Dialysis Transplantation, 2018, 33, 138-148.	0.4	62
6	Clinical and pathological predictors of estimated GFR decline in patients with type 2 diabetes and overt proteinuric diabetic nephropathy. Diabetes/Metabolism Research and Reviews, 2015, 31, 572-581.	1.7	50
7	Quality of life of patients with ADPKD—Toranomon PKD QOL study: cross-sectional study. BMC Nephrology, 2013, 14, 179.	0.8	43
8	A Pathological Scoring System to Predict Renal Outcome in Diabetic Nephropathy. American Journal of Nephrology, 2015, 41, 337-344.	1.4	41
9	Denosumab for Low Bone Mass in Hemodialysis Patients: A Noncontrolled Trial. American Journal of Kidney Diseases, 2015, 66, 175-177.	2.1	39
10	Intravascular Embolization Therapy in Patients With EnlargedÂPolycystic Liver. American Journal of Kidney Diseases, 2014, 63, 937-944.	2.1	37
11	Conditions, pathogenesis, and progression of diabetic kidney disease and early decliner in Japan. BMJ Open Diabetes Research and Care, 2020, 8, e000902.	1.2	31
12	Clinicopathological analysis of biopsy-proven diabetic nephropathy based on the Japanese classification of diabetic nephropathy. Clinical and Experimental Nephrology, 2018, 22, 570-582.	0.7	28
13	Successful treatment with humanized anti–interleukin-6 receptor antibody (tocilizumab) in a case of AA amyloidosis complicated by familial Mediterranean fever. Modern Rheumatology, 2016, 26, 610-613.	0.9	27
14	Suitability of Patients with Autosomal Dominant Polycystic Kidney Disease for Renal Transcatheter Arterial Embolization. Journal of the American Society of Nephrology: JASN, 2016, 27, 2177-2187.	3.0	24
15	A new pathological scoring system by the Japanese classification to predict renal outcome in diabetic nephropathy. PLoS ONE, 2018, 13, e0190923.	1.1	24
16	Nodular lesions in diabetic nephropathy: Collagen staining and renal prognosis. Diabetes Research and Clinical Practice, 2017, 127, 187-197.	1.1	22
17	Clinicopathological predictors for progression of chronic kidney disease in nephrosclerosis: a biopsy-based cohort study. Nephrology Dialysis Transplantation, 2019, 34, 1182-1188.	0.4	22
18	Clinical implications of linear immunofluorescent staining for immunoglobulin G in patients with diabetic nephropathy. Diabetes Research and Clinical Practice, 2014, 106, 522-530.	1.1	20

#	Article	IF	Citations
19	Shaping Up Mitochondria in Diabetic Nephropathy. Kidney360, 2020, 1, 982-992.	0.9	20
20	Podocyte autophagy is associated with foot process effacement and proteinuria in patients with minimal change nephrotic syndrome. PLoS ONE, 2020, 15, e0228337.	1.1	20
21	Renal expression of trefoil factor 3 mRNA in association with tubulointerstitial fibrosis in IgA nephropathy. Nephrology, 2018, 23, 855-862.	0.7	19
22	TAFRO syndrome with refractory thrombocytopenia responding to tocilizumab and romiplostim: a case report. CEN Case Reports, 2018, 7, 162-168.	0.5	18
23	Value of adding the renal pathological score to the kidney failure risk equation in advanced diabetic nephropathy. PLoS ONE, 2018, 13, e0190930.	1.1	18
24	Clinicopathological analysis of allogeneic hematopoietic stem cell transplantation–related membranous glomerulonephritis. Human Pathology, 2016, 50, 187-194.	1.1	17
25	Cyst infection in autosomal dominant polycystic kidney disease: penetration of meropenem into infected cysts. BMC Nephrology, 2018, 19, 272.	0.8	16
26	Mitochondrial Regulation of Diabetic Kidney Disease. Frontiers in Medicine, 2021, 8, 745279.	1.2	15
27	Long term follow up of congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman) Tj ETQq1 1 0.784	4314.ggBT	  Overlock 1 <mark>0</mark>
28	Nationwide multicenter kidney biopsy study of Japanese patients with hypertensive nephrosclerosis. Clinical and Experimental Nephrology, 2018, 22, 629-637.	0.7	14
29	Urine Trefoil Factors as Prognostic Biomarkers in Chronic Kidney Disease. BioMed Research International, 2018, 2018, 1-11.	0.9	14
30	Role for carbohydrate response element-binding protein (ChREBP) in high glucose-mediated repression of long noncoding RNA Tug1. Journal of Biological Chemistry, 2020, 295, 15840-15852.	1.6	14
31	Paratubular basement membrane insudative lesions predict renal prognosis in patients with type 2 diabetes and biopsy-proven diabetic nephropathy. PLoS ONE, 2017, 12, e0183190.	1.1	14
32	Significance of Small Renal Artery Lesions in Patients with Antineutrophil Cytoplasmic Antibody-associated Glomerulonephritis. Journal of Rheumatology, 2014, 41, 1140-1146.	1.0	13
33	Identification of Novel Urinary Biomarkers for Predicting Renal Prognosis in Patients With Type 2 Diabetes by Glycan Profiling in a Multicenter Prospective Cohort Study: U-CARE Study 1. Diabetes Care, 2018, 41, 1765-1775.	4.3	13
34	PGC1α is required for the renoprotective effect of lncRNA Tug1 inÂvivo and links Tug1 with urea cycle metabolites. Cell Reports, 2021, 36, 109510.	2.9	13
35	Destructive Spondyloarthropathy in Patients on Longâ€Term Peritoneal Dialysis or Hemodialysis. Therapeutic Apheresis and Dialysis, 2015, 19, 393-398.	0.4	12
36	Survival after arterial embolization therapy in patients with polycystic kidney and liver disease. Journal of Nephrology, 2015, 28, 369-377.	0.9	11

#	Article	IF	CITATIONS
37	Ursodeoxycholic Acid for Treatment of Enlarged Polycystic Liver. Therapeutic Apheresis and Dialysis, 2016, 20, 73-78.	0.4	11
38	Arterial Stiffness is an Independent Risk Factor for Anemia After Percutaneous Native Kidney Biopsy. Kidney and Blood Pressure Research, 2017, 42, 284-293.	0.9	11
39	Urine 5MedC, a Marker of DNA Methylation, in the Progression of Chronic Kidney Disease. Disease Markers, 2019, 2019, 1-10.	0.6	11
40	Peritoneal Dialysis is Limited by Kidney and Liver Volume in Autosomal Dominant Polycystic Kidney Disease. Therapeutic Apheresis and Dialysis, 2015, 19, 207-211.	0.4	10
41	Tocilizumab for AA Amyloidosis after Treatment of Multicentric Castleman Disease with Steroids, Chemotherapy and Rituximab for Over 20 Years. Internal Medicine, 2015, 54, 3215-3219.	0.3	9
42	Novel urinary glycan profiling by lectin array serves as the biomarkers for predicting renal prognosis in patients with IgA nephropathy. Scientific Reports, 2021, 11, 3394.	1.6	9
43	Characteristics of Intravascular Large B-Cell Lymphoma Limited to the Glomerular Capillaries: A Case Report. Case Reports in Nephrology and Dialysis, 2015, 5, 173-179.	0.3	8
44	Effect of Proteinuria and Glomerular Filtration Rate on Renal Outcome in Patients with Biopsy-Proven Benign Nephrosclerosis. PLoS ONE, 2016, 11, e0147690.	1.1	8
45	Clinical and histological features of antineutrophil cytoplasmic antibody-associated vasculitis related to antithyroid drugs. Clinical Nephrology, 2018, 89, 438-444.	0.4	8
46	Osteomalacia and Insufficiency Fracture in a Hemodialysis Patient with Autosomal Dominant Polycystic Kidney Disease. Internal Medicine, 2012, 51, 3277-3280.	0.3	7
47	lgG4-related Disease: A Mass Lesion in the Intrarenal Sinus near the Renal Pelvis. Internal Medicine, 2015, 54, 1897-1900.	0.3	7
48	Two Types of Renovascular Lesions in Lupus Nephritis with Clinical Thrombotic Thrombocytopenic Purpura. Case Reports in Nephrology and Dialysis, 2015, 5, 192-199.	0.3	7
49	ANCA-Associated Vasculitis in a Patient with Systematic Sclerosis and Sjögren's Syndrome: A Case Report. Case Reports in Nephrology and Dialysis, 2015, 5, 113-117.	0.3	7
50	A clinical staging score to measure the severity of dialysis-related amyloidosis. Clinical and Experimental Nephrology, 2017, 21, 300-306.	0.7	7
51	Clinical and pathological features of antiâ€neutrophil cytoplasmic antibodyâ€associated vasculitis in patients with minor urinary abnormalities. Nephrology, 2018, 23, 1007-1012.	0.7	7
52	Prediction of hepatic cyst recurrence after minocycline hydrochloride aspiration sclerotherapy using cyst computed tomography values. Hepatology Research, 2017, 47, 419-424.	1.8	6
53	Anti-RNA polymerase III antibody-associated scleroderma renal crisis in a patient with limited cutaneous systemic sclerosis: A case report. Modern Rheumatology, 2018, 28, 369-372.	0.9	6
54	Cushing's Syndrome after Hemodialysis for 21 Years. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 13-19.	1.8	5

#	Article	IF	CITATIONS
55	Castleman's Disease Accompanied by Hypolipidemic Cerebral Hemorrhage and Nephrosclerosis. Internal Medicine, 2013, 52, 1611-1616.	0.3	4
56	Cryoglobulinemic vasculitis with primary Sjögren's syndrome: A case report. Modern Rheumatology, 2018, 28, 570-574.	0.9	4
57	Hepatocellular Carcinoma in a Patient with Polycystic Liver Disease. Internal Medicine, 2015, 54, 1891-1896.	0.3	3
58	Sleep-Disordered Breathing in Patients with Polycystic Liver and Kidney Disease Referred for Transcatheter Arterial Embolization. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 949-956.	2.2	3
59	Umbilical hernia in autosomal dominant polycystic kidney disease. Clinical and Experimental Nephrology, 2015, 19, 154-156.	0.7	3
60	Five Sequential Evaluations of Renal Histology in a Patient with Light Chain Deposition Disease. Internal Medicine, 2016, 55, 2993-2999.	0.3	3
61	Kidney transplantation for a patient with refractory childhood-onset ANCA-associated vasculitis. Modern Rheumatology, 2016, 26, 307-309.	0.9	3
62	Novel Urinary Glycan Biomarkers Predict Cardiovascular Events in Patients With Type 2 Diabetes: A Multicenter Prospective Study With 5-Year Follow Up (U-CARE Study 2). Frontiers in Cardiovascular Medicine, 2021, 8, 668059.	1.1	3
63	Phospholipase A2 Receptor-Positive Idiopathic Membranous Glomerulonephritis with Onset at 95 Years: Case Report. Case Reports in Nephrology and Dialysis, 2016, 6, 76-82.	0.3	2
64	AA-negative and Kappa-positive Amyloidosis in a Patient with Rheumatoid Arthritis. Internal Medicine, 2016, 55, 2491-2495.	0.3	2
65	Daughter and mother with orofaciodigital syndrome type 1 and glomerulocystic kidney disease. Human Pathology, 2016, 55, 24-29.	1.1	2
66	Amplified Association Between Blood Pressure and Albuminuria in Overweight Patients With Biopsy-Proven Hypertensive Nephrosclerosis. American Journal of Hypertension, 2019, 32, 486-491.	1.0	2
67	Variegate porphyria complicated by systemic AA amyloidosis: a case report. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 272-274.	1.4	1
68	Hemodialysis without Anticoagulation for a Patient with Chronic Disseminated Intravascular Coagulation. Case Reports in Nephrology and Dialysis, 2014, 4, 25-30.	0.3	1
69	Adynamic bone disease: a 14-year case report. Kidney International, 2014, 85, 217.	2.6	1
70	Development of Urinary Diagnostic Biomarker for IgA Nephropathy by Lectin Microarray. American Journal of Nephrology, 2022, 53, 10-20.	1.4	1
71	A Patient with Type 3 Autoimmune Polyglandular Syndrome who Developed Systemic Lupus Erythematosus 8 years after the Diagnosis of Autoimmune Hepatitis. Acta Medica Okayama, 2019, 73, 367-372.	0.1	1
72	IgG4-Related Disease and Malignant Tumor. , 2014, , 219-224.		0

#	Article	IF	CITATIONS
73	V. Biomarkers for Predicting Development and Progression of DKD. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 928-936.	0.0	O
74	The 2018 Incentive Award of the Okayama Medical Association in General Medical Science (2018 Yuuki) Tj ETQo	10 Q.O.rgB	T /Qverlock 10
75	Nondiabetic Renal Disease (NDRD) and Diabetic Kidney Disease (DKD)., 2021,, 159-171.		O
76	Analysis of inflammatory cytokines and estimated glomerular filtration rate decline in Japanese patients with diabetic kidney disease: a pilot study. Biomarkers in Medicine, 2022, , .	0.6	0